5月25日，据CDE官网消息，上海民为生物技术有限公司联合申请药品“MWX203注射液”，获得临床试验默示许可，受理号CXHL2500270。
公示信息显示，药品“MWX203注射液”适应症：血脂异常。
上海民为生物技术有限公司，成立于2021年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本1521.6048万人民币。
通过天眼查大数据分析，上海民为生物技术有限公司共对外投资了1家企业，参与招投标项目2次，专利信息11条，此外企业还拥有行政许可6个。
主要股东信息显示，上海民为生物技术有限公司由乐普（北京）医疗器械股份有限公司持股54.5%、韩为跃持股26.9781%、青岛民芯创业投资中心（有限合伙）持股11.5503%、汉康中小企业发展基金（潍坊）合伙企业（有限合伙）持股5%、东莞云瀚企业管理中心（有限合伙）持股1.9716%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.